This section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Article content
Integrating MyMedi.ca healthcare provider-guided medical cannabis care into hospitals, specialty clinics, insurers and multidisciplinary healthcare networks in Canada
Sign In or Create an Account
or View more offersArticle content
TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”), a commercial-stage international biopharmaceutical company focused on cannabinoid-based medicines, is pleased to announce the MyMedi.ca Integrated Healthcare Program (“Program”), a new program designed to integrate medical cannabis care and patient support into Canadian healthcare institutions and clinical networks.
Article contentWe apologize, but this video has failed to load.Try refreshing your browser, or
tap here to see other videos from our team.Article content
Story continues below
This advertisement has not loaded yet, but your article continues below.
Article content
The program extends the MyMedi.ca platform beyond traditional medical cannabis and referral channels and is intended to support hospitals, specialty clinics, multidisciplinary healthcare networks, insurers and other healthcare organizations seeking to incorporate structured medical cannabis pathways into their existing models of care. The Program extends access to a focused medical cannabis formulary, pharmacist-led patient support, healthcare provider (HCP) treatment planning and education as well as reimbursement and insurance.
Article contentArticle content
“An important next step in the evolution of medical cannabis is furthering integration and access within established healthcare environments,” said Aras Azadian, Chief Executive Officer of Avicanna. “Building on a decade of research and collaboration with the Canadian medical community, this new Program further supports hospitals, clinics and healthcare networks, with the specialized infrastructure and support to incorporate medical cannabis into existing models of care. For patients, this opens additional access to HCP-led care, individualized treatment support and insurance coverage with the aim of improving treatment outcomes.”
Article content
Story continues below
This advertisement has not loaded yet, but your article continues below.
Article content
Building on MyMedi.ca’s Established Infrastructure and Proven Healthcare Integration
The Program builds on Avicanna’s work with leading Canadian hospitals, healthcare institutions and medical professionals on clinical research and cannabinoid access. This includes the Sunnybrook Odette Cancer Centre pilot, which brought medical cannabis support into an established oncology setting and helped refine the patient pathways, educational frameworks and support models behind the program.
Article content
Addressing a Gap in Medical Cannabis Access
Medical cannabis use in Canada extends well beyond patients in the federally regulated medical access framework, with Health Canada’s 2024 Canadian Cannabis Survey reporting that only 18% of Canadians using cannabis for medical purposes did so with a medical document from a healthcare professional. This points to a gap in medically guided care, with many patients potentially managing symptoms without structured treatment planning, product and dosing guidance, medication review, reimbursement support or ongoing clinical follow-up.
